193 related articles for article (PubMed ID: 30228234)
1.
Tara S; Isshiki Y; Nakajima-Takagi Y; Oshima M; Aoyama K; Tanaka T; Shinoda D; Koide S; Saraya A; Miyagi S; Manabe I; Matsui H; Koseki H; Bardwell VJ; Iwama A
Blood; 2018 Dec; 132(23):2470-2483. PubMed ID: 30228234
[No Abstract] [Full Text] [Related]
2. Internal deletion of BCOR reveals a tumor suppressor function for BCOR in T lymphocyte malignancies.
Tanaka T; Nakajima-Takagi Y; Aoyama K; Tara S; Oshima M; Saraya A; Koide S; Si S; Manabe I; Sanada M; Nakayama M; Masuko M; Sone H; Koseki H; Iwama A
J Exp Med; 2017 Oct; 214(10):2901-2913. PubMed ID: 28827447
[TBL] [Abstract][Full Text] [Related]
3. Functional loss of a noncanonical BCOR-PRC1.1 complex accelerates SHH-driven medulloblastoma formation.
Kutscher LM; Okonechnikov K; Batora NV; Clark J; Silva PBG; Vouri M; van Rijn S; Sieber L; Statz B; Gearhart MD; Shiraishi R; Mack N; Orr BA; Korshunov A; Gudenas BL; Smith KS; Mercier AL; Ayrault O; Hoshino M; Kool M; von Hoff K; Graf N; Fleischhack G; Bardwell VJ; Pfister SM; Northcott PA; Kawauchi D
Genes Dev; 2020 Sep; 34(17-18):1161-1176. PubMed ID: 32820036
[TBL] [Abstract][Full Text] [Related]
4. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.
An N; Khan S; Imgruet MK; Gurbuxani SK; Konecki SN; Burgess MR; McNerney ME
Blood; 2018 Jun; 131(24):2682-2697. PubMed ID: 29592892
[TBL] [Abstract][Full Text] [Related]
5. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
[TBL] [Abstract][Full Text] [Related]
6. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
[TBL] [Abstract][Full Text] [Related]
7. PRC2 insufficiency causes p53-dependent dyserythropoiesis in myelodysplastic syndrome.
Aoyama K; Shinoda D; Suzuki E; Nakajima-Takagi Y; Oshima M; Koide S; Rizq O; Si S; Tara S; Sashida G; Iwama A
Leukemia; 2021 Apr; 35(4):1156-1165. PubMed ID: 32820269
[TBL] [Abstract][Full Text] [Related]
8. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
[TBL] [Abstract][Full Text] [Related]
9. KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis.
Isshiki Y; Nakajima-Takagi Y; Oshima M; Aoyama K; Rizk M; Kurosawa S; Saraya A; Kondo T; Sakaida E; Nakaseko C; Yokote K; Koseki H; Iwama A
Blood Adv; 2019 Sep; 3(17):2537-2549. PubMed ID: 31471323
[TBL] [Abstract][Full Text] [Related]
10. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.
Abdel-Wahab O; Gao J; Adli M; Dey A; Trimarchi T; Chung YR; Kuscu C; Hricik T; Ndiaye-Lobry D; Lafave LM; Koche R; Shih AH; Guryanova OA; Kim E; Li S; Pandey S; Shin JY; Telis L; Liu J; Bhatt PK; Monette S; Zhao X; Mason CE; Park CY; Bernstein BE; Aifantis I; Levine RL
J Exp Med; 2013 Nov; 210(12):2641-59. PubMed ID: 24218140
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY
Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985
[TBL] [Abstract][Full Text] [Related]
12. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.
Badaat I; Mirza S; Padron E; Sallman D; Komrokji R; Song J; Hussaini MO
J Clin Pathol; 2020 Apr; 73(4):209-212. PubMed ID: 31771970
[TBL] [Abstract][Full Text] [Related]
13. Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis.
Kelly MJ; So J; Rogers AJ; Gregory G; Li J; Zethoven M; Gearhart MD; Bardwell VJ; Johnstone RW; Vervoort SJ; Kats LM
Nat Commun; 2019 Mar; 10(1):1347. PubMed ID: 30902969
[TBL] [Abstract][Full Text] [Related]
14. A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations.
Li X; Xu F; Wu LY; Zhao YS; Guo J; He Q; Zhang Z; Chang CK; Wu D
Sci Rep; 2020 Jan; 10(1):826. PubMed ID: 31964915
[TBL] [Abstract][Full Text] [Related]
15. PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia.
Guirguis AA; Slape CI; Failla LM; Saw J; Tremblay CS; Powell DR; Rossello F; Wei A; Strasser A; Curtis DJ
Cell Death Differ; 2016 Jun; 23(6):1049-59. PubMed ID: 26742432
[TBL] [Abstract][Full Text] [Related]
16. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
Man N; Mas G; Karl DL; Sun J; Liu F; Yang Q; Torres-Martin M; Itonaga H; Martinez C; Chen S; Xu Y; Duffort S; Hamard PJ; Chen C; Zucconi BE; Cimmino L; Yang FC; Xu M; Cole PA; Figueroa ME; Nimer SD
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622806
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
18. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
Damm F; Chesnais V; Nagata Y; Yoshida K; Scourzic L; Okuno Y; Itzykson R; Sanada M; Shiraishi Y; Gelsi-Boyer V; Renneville A; Miyano S; Mori H; Shih LY; Park S; Dreyfus F; Guerci-Bresler A; Solary E; Rose C; Cheze S; Prébet T; Vey N; Legentil M; Duffourd Y; de Botton S; Preudhomme C; Birnbaum D; Bernard OA; Ogawa S; Fontenay M; Kosmider O
Blood; 2013 Oct; 122(18):3169-77. PubMed ID: 24047651
[TBL] [Abstract][Full Text] [Related]
19. Clarifying the impact of polycomb complex component disruption in human cancers.
Yamamoto Y; Abe A; Emi N
Mol Cancer Res; 2014 Apr; 12(4):479-84. PubMed ID: 24515802
[TBL] [Abstract][Full Text] [Related]
20. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.
Mochizuki-Kashio M; Aoyama K; Sashida G; Oshima M; Tomioka T; Muto T; Wang C; Iwama A
Blood; 2015 Sep; 126(10):1172-83. PubMed ID: 26219303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
